The DOI matches its Crossref record.
Crystal Structures of MEK1 Binary and Ternary Complexes with Nucleotides and Inhibitors
Abstract
MEK1 is a member of the MAPK signal transduction pathway that responds to growth factors and cytokines. We have determined that the kinase domain spans residues 35-382 by proteolytic cleavage. The complete kinase domain has been crystallized and its X-ray crystal structure as a complex with magnesium and ATP-gammaS determined at 2.1 A. Unlike crystals of a truncated kinase domain previously published, the crystals of the intact domain can be grown either as a binary complex with a nucleotide or as a ternary complex with a nucleotide and one of a multitude of allosteric inhibitors. Further, the crystals allow for the determination of costructures with ATP competitive inhibitors. We describe the structures of nonphosphorylated MEK1 (npMEK1) binary complexes with ADP and K252a, an ATP-competitive inhibitor (see Table 1), at 1.9 and 2.7 A resolution, respectively. Ternary complexes have also been solved between npMEK1, a nucleotide, and an allosteric non-ATP competitive inhibitor: ATP-gammaS with compound 1 and ADP with either U0126 or the MEK1 clinical candidate PD325089 at 1.8, 2.0, and 2.5 A, respectively. Compound 1 is structurally similar to PD325901. These structures illustrate fundamental differences among various mechanisms of inhibition at the molecular level. Residues 44-51 have previously been shown to play a negative regulatory role in MEK1 activity. The crystal structure of the integral kinase domain provides a structural rationale for the role of these residues. They form helix A and repress enzymatic activity by stabilizing an inactive conformation in which helix C is displaced from its active state position. Finally, the structure provides for the first time a molecular rationale that explains how mutations in MEK may lead to the cardio-facio-cutaneous syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The oxytocin receptor: from intracellular signaling to behavior
Jurek, B., & Neumann, I. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00031.2017 · Cited by 999
Molecular Recognition in Chemical and Biological Systems
Persch, E., Dumele, O., & Diederich, F. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201408487 · Cited by 654
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606
The clinical development of MEK inhibitors
Zhao, Y., & Adjei, A. A. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.83 · Cited by 400
Greger, J. G., Eastman, S. D., Zhang, V., Bleam, M. R., Hughes, A. M., Smitheman, K. N., Dickerson, S. H., Laquerre, S. G., Liu, L., & Gilmer, T. M. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0989 · Cited by 363
A Novel Role for Copper in Ras/Mitogen-Activated Protein Kinase Signaling
Turski, M. L., Brady, D. C., Kim, H. J., Kim, B.-E., Nose, Y., Counter, C. M., Winge, D. R., & Thiele, D. J. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.05722-11 · Cited by 320
Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
Park, E., Rawson, S., Li, K., Kim, B.-W., Ficarro, S. B., Pino, G. G.-D., Sharif, H., Marto, J. A., Jeon, H., & Eck, M. J. (2019) · Nature · doi:10.1038/s41586-019-1660-y · Cited by 309
Mosaic RAS/MAPK variants cause sporadic vascular malformations which respond to targeted therapy
Al-Olabi, L., Polubothu, S., Dowsett, K., Andrews, K. A., Stadnik, P., Joseph, A. P., Knox, R., Pittman, A., Clark, G., Baird, W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98589 · Cited by 292
MEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
MEK1/2 dual-specificity protein kinases: Structure and regulation
Roskoski, R. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.145 · Cited by 276
High prevalence of MAP2K1 mutations in variant and IGHV4-34–expressing hairy-cell leukemias
Waterfall, J. J., Arons, E., Walker, R. L., Pineda, M., Roth, L., Killian, J. K., Abaan, O. D., Davis, S. R., Kreitman, R. J., & Meltzer, P. S. (2014) · Nature Genetics · doi:10.1038/ng.2828 · Cited by 276
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
Brennan, D. F., Dar, A. C., Hertz, N. T., Chao, W. C. H., Burlingame, A. L., Shokat, K. M., & Barford, D. (2011) · Nature · doi:10.1038/nature09860 · Cited by 254
Structural basis for the action of the drug trametinib at KSR-bound MEK
Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., Scopton, A. P., & Dar, A. C. (2020) · Nature · doi:10.1038/s41586-020-2760-4 · Cited by 178
Matsumoto, T., Kinoshita, T., Kirii, Y., Yokota, K., Hamada, K., & Tada, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.071 · Cited by 49
Metadata
- Authors
- Fischmann, T. O., Smith, C. K., Mayhood, T. W., Myers, J. E., Reichert, P., Mannarino, A., Carr, D., Zhu, H., Wong, J., Yang, R.-S., Le, H. V., & Madison, V. S.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-01-22
- Volume
- 48
- Issue
- 12
- Pages
- 2661-2674
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W1981602821
- Cited by
- 183
- References
- 0
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.